Form 4: GoodRx Director Douglas Hirsch Receives Stock Units

Director Douglas Hirsch was granted 73,434 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.

Summary

• Director Douglas Hirsch acquired 73,434 deferred stock units (DSUs) on June 16, 2026.
• Each DSU represents a contingent right to receive one share of Class A common stock.
• The units vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
• Settlement of the units is deferred until 2029, separation from service, change in control, death, or disability.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a director.

Risks

• Vesting is contingent upon the director's continued service through the vesting date.

Future Outlook

The units are scheduled to vest in 2027, with settlement deferred until 2029 or upon specific triggering events such as separation from service or a change in control.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the healthcare technology sector to ensure long-term commitment and alignment with corporate governance standards.

Comparison to Industry Standards

• The use of deferred stock units for director compensation is consistent with practices at other mid-cap technology and healthcare companies.
• The vesting schedule aligns with typical annual meeting cycles observed in public company governance.

Corporate Governance

Related Party Transactions

• The filing discloses holdings in various Grantor Retained Annuity Trusts (GRATs) associated with the director and his spouse.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity grant.

Next Steps

• Vesting of the 73,434 deferred stock units on the earlier of June 16, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

GoodRx, GDRX, Director Compensation, Form 4, Insider Transaction, Equity Grant